I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Comparative efficacy and safety of subcutaneous infliximab ..:
Peyrin‐Biroulet, Laurent
;
Arkkila, Perttu
;
Armuzzi, Alessandro
...
10.1186/s12876-024-03163-5. , 2024
Link:
http://hdl.handle.net/10138/574634
RT Journal T1
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials
UL https://suche.suub.uni-bremen.de/peid=base-ftunivhelsihelda:oai:helda.helsinki.fi:10138_574634&Exemplar=1&LAN=DE A1 Peyrin‐Biroulet, Laurent A1 Arkkila, Perttu A1 Armuzzi, Alessandro A1 Danese, Silvio A1 Ferrante, Marc A1 Jordi Guardiola A1 Jahnsen, Jørgen A1 Louis, Edouard A1 Lukáš, Milan A1 Reinisch, Walter A1 Roblin, Xavier A1 Smith, Philip J A1 Kwon, Taek A1 Kim, Jeeyoung A1 Yoon, Sangwook A1 Kim, Dong Hyeon A1 Atreya, Raja PB BioMed Central YR 2024 K1 Biobetter K1 Bioinnovative K1 Inflammatory bowel disease K1 Subcutaneous infliximab K1 Tumour necrosis factor-α inhibitors K1 Vedolizumab K1 General medicine K1 internal medicine and other clinical medicine JF 10.1186/s12876-024-03163-5 LK http://hdl.handle.net/10138/574634 DO http://hdl.handle.net/10138/574634 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)